2-Cycloheptylimidazol | 91010-27-4

• 英文名称: 2-Cycloheptylimidazol
• 英文别名: 2-cycloheptyl-1H-imidazole；2-cycloheptyl-1H-imidazole
• CAS: 91010-27-4
• 化学式: C₁₀H₁₆N₂
• 分子量: 164.25
• InChiKey: RFSSSPDXLQUWJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
  申请人：——

  公开号：US20030055070A1

  公开（公告）日：2003-03-20

  This invention is directed to the use phosphodiesterase type 5 (PDE5) inhibitors in the treatment of selective serotonin reuptake inhibitor (SSRI) induced sexual dysfunction. Specifically, this invention is directed to a method for treating an animal to cure; prevent or ameliorate SSRI induced sexual dysfunction which comprises administering to the animal an effective amount of the inhibitor. The animal may be a male or a female human. The invention also includes the use of such inhibitors in the manufacture of a medicament to prevent; cure or ameliorate SSRI induced sexual dysfunction. Moreover, the invention includes a kit comprising a SSRI, such as sertraline, fluoxetine, paroxetine, and a PDE5 inhibitor, such as sildenafil citrate, for the treatment or prevention of serotonergic associated disorders such as depression, obsessive compulsive disorder or panic disorder, while reducing or preventing sexual dysfunction.

  该发明涉及使用磷酸二酯酶-5（PDE5）抑制剂治疗选择性血清素再摄取抑制剂（SSRI）引起的性功能障碍。具体而言，该发明涉及一种治疗动物以治愈、预防或改善SSRI引起的性功能障碍的方法，包括向动物施用有效量的抑制剂。该动物可以是男性或女性人类。该发明还包括将这些抑制剂用于制造药物以预防、治愈或改善SSRI引起的性功能障碍。此外，该发明还包括一种套装，其中包括SSRI（如舍曲林、氟西汀、帕罗西汀）和PDE5抑制剂（如西地那非）用于治疗或预防血清素相关疾病，如抑郁症、强迫症或惊恐症，同时减少或预防性功能障碍。
• Methods and compositions for treating diseases and conditions of the eye
  申请人：——

  公开号：US20020119974A1

  公开（公告）日：2002-08-29

  Methods for the prevention and treatment of diseases and conditions of the eye including, but are not limited to: central retinal artery occlusion; central retinal vein occlusion; optic neuropathy including, but not limited to, anterior ischemic optic neuropathy and glaucomatous optic neuropathy; and macular (dry) degeneration are disclosed. These methods comprise administering to a patient a prophylactically or therapeutically effective amount of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type 5 inhibitor. Pharmaceutical compositions and dosage forms comprising cyclic guanosine 3′,5′-monophosphate phosphodiesterase type 5 inhibitors are also disclosed.

  披露了预防和治疗眼部疾病和病况的方法，包括但不限于：中央视网膜动脉阻塞；中央视网膜静脉阻塞；视神经病变，包括但不限于前部缺血性视神经病变和青光眼性视神经病变；以及黄斑（干性）变性。这些方法包括向患者投予预防性或治疗性有效量的环鸟苷3′,5′-单磷酸磷酸二酯酶类型5抑制剂。还披露了含有环鸟苷3′,5′-单磷酸磷酸二酯酶类型5抑制剂的药物组合物和剂型。
• [EN] BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS<br/>[FR] BIPHENYL SULFONAMIDES EN TANT QUE DOUBLES ANTAGONISTES DE RECEPTEURS D'ANGIOTENSINE ET D'ENDOTHELINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2000001389A1

  公开（公告）日：2000-01-13

  Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.

  本发明涉及一种新型的联合血管紧张素和内皮素受体拮抗剂的双苯基磺酰胺类化合物，以及使用这些化合物治疗高血压和其他疾病的方法，以及含有这些化合物的制药组合物。
• [EN] BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS<br/>[FR] BIPHENYL SULFONAMIDES UTILISES COMME DOUBLES ANTAGONISTES DES RECEPTEURS DE L'ANGIOTENSINE ET DE L'ENDOTHELINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2001044239A2

  公开（公告）日：2001-06-21

  Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.

  本专利申请涉及一种新型的联合血管紧张素和内皮素受体拮抗剂的新型二苯基磺酰胺化合物，以及使用这些化合物治疗高血压和其他疾病的方法，同时还包括含有这些化合物的制药组合物。
• cGMP PDE 5 Inhibitors for inhalation in the treatment of sexual dysfunction
  申请人：——

  公开号：US20010055570A1

  公开（公告）日：2001-12-27

  Treatment of sexual dysfunction by inhalation of a cGMP PDE 5 inhibitor, especially 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl) quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl) quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one or 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin-4-one.

  通过吸入cGMP PDE 5抑制剂治疗性功能障碍，特别是5-[2-乙氧基-5-(4-甲基哌嗪磺酰基)苯基]-1-甲基-3-正丙基-1,6-二氢-7H-吡唑并[4,3-d]嘧啶-7-酮、4-苯甲基氨基-6-氯-2-(1-咪唑基)喹唑啉、4-苯甲基氨基-6-氯-2-(3-吡啶基)喹唑啉、1,3-二甲基-6-(2-丙氧基-5-甲烷磺酰胺基苯基)-1,5-二氢-吡唑并[3,4-d]嘧啶-4-酮或1-环戊基-3-乙基-6-(3-乙氧基-4-吡啶基)-吡唑并[3,4-d]嘧啶-4-酮。